-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIEF-Regenxbio Highlights Key 2026 Catalysts And Announces Positive Long-Term Functional Outcomes In Lead Duchenne Gene Therapy Program

Reuters·01/11/2026 20:01:47

Please log in to view news